Clinuvel Pharm Ords (CLVLF) 1.9400 $CLVLF
Vitiligo Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dh68bp/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Biocon Limited - Bristol-Myers Squibb Company - Clinuvel Pharmaceuticals Limited - Reliance Life Sciences Pvt. Ltd. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - abatacept (recombinant) - ACH-24 - afamelanotide - Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - itolizumab - ReliDerm-M - SUN-0597 For more information visit http://www.researchandmarkets.com/research/dh68bp/vitiligo
BMY: 59.22 (+0.47)
Actinic (Solar) Keratosis Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkb4rv/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 3M Drug Delivery Systems - Advancell - Biofrontera AG - Clinuvel Pharmaceuticals Limited - Digna Biotech, S.L. - Dolorgiet Gmbh & Co. Kg - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Galderma S.A. - Kinex Pharmaceuticals, LLC - LEO Pharma A/S - Novartis AG - Novelix Pharmaceuticals, Inc. - Promius Pharma, LLC - RestorGenex Corporation - Spherium Biomed S.L. For more information visit http://www.researchandmarkets.com/research/vk...inic_solar
FOMX: 9.95 (-0.04), NVS: 96.55 (+0.28)
Global Pemphigus Pipeline Report 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4jpj9/pemphigus) has announced the addition of the "Pemphigus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Clinuvel Pharmaceuticals Limited - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - PinCell srl Drug Profiles - afamelanotide - Antibody for Autoimmune Disorders and Inflammation - DP-C006 - Drugs to Target HSP27 for Autoimmune Disorders - HL-161 - ofatumumab - PC-111 - VAY-736 - veltuzumab - Pemphigus For more information visit http://www.researchandmarkets.com/research/l4jpj9/pemphigus
IMMU: 2.22 (+0.01), MNTA: 18.99 (-0.04), NVS: 96.55 (+0.28)
Vitiligo - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/sp334p/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vitiligo - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Reliance Life Sciences - Biocon Limited - Galderma - Sun Pharmaceutical Industries - Clinuvel Pharmaceuticals - Ache Laboratorios Farmaceuticos - SWITCH Biotech For more information visit http://www.researchandmarkets.com/research/sp334p/vitiligo
Market Maker Surveillance Report. RITT, GNI, GTI, GLYC, CLVLY, PULS, Losing Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), Great Northern Iron Ore Properties (NYSE:GNI), Graftech International Ltd (NYSE:GTI), GLYCOMED INC (NASDAQ:GLYC), Clinuvel Pharmaceuticals Ltd (OTC:CLVLY), Pulse Electronics Corp (NYSE
ULS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GLYC: 7.10 (+0.09), GTI: 5.05 (+0.01), RITT: 1.38 (+0.05), GNI: 8.10 (+0.67)
Vitiligo Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dh68bp/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Biocon Limited - Bristol-Myers Squibb Company - Clinuvel Pharmaceuticals Limited - Reliance Life Sciences Pvt. Ltd. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - abatacept (recombinant) - ACH-24 - afamelanotide - Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - itolizumab - ReliDerm-M - SUN-0597 For more information visit http://www.researchandmarkets.com/research/dh68bp/vitiligo
BMY: 59.22 (+0.47)
Actinic (Solar) Keratosis Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkb4rv/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 3M Drug Delivery Systems - Advancell - Biofrontera AG - Clinuvel Pharmaceuticals Limited - Digna Biotech, S.L. - Dolorgiet Gmbh & Co. Kg - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Galderma S.A. - Kinex Pharmaceuticals, LLC - LEO Pharma A/S - Novartis AG - Novelix Pharmaceuticals, Inc. - Promius Pharma, LLC - RestorGenex Corporation - Spherium Biomed S.L. For more information visit http://www.researchandmarkets.com/research/vk...inic_solar
FOMX: 9.95 (-0.04), NVS: 96.55 (+0.28)
Global Pemphigus Pipeline Report 2015 - 7 Companies & 10 Drug Profiles
M2 - Thu May 21, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l4jpj9/pemphigus) has announced the addition of the "Pemphigus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Clinuvel Pharmaceuticals Limited - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - PinCell srl Drug Profiles - afamelanotide - Antibody for Autoimmune Disorders and Inflammation - DP-C006 - Drugs to Target HSP27 for Autoimmune Disorders - HL-161 - ofatumumab - PC-111 - VAY-736 - veltuzumab - Pemphigus For more information visit http://www.researchandmarkets.com/research/l4jpj9/pemphigus
IMMU: 2.22 (+0.01), MNTA: 18.99 (-0.04), NVS: 96.55 (+0.28)
Vitiligo - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/sp334p/vitiligo) has announced the addition of the "Vitiligo - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vitiligo - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Reliance Life Sciences - Biocon Limited - Galderma - Sun Pharmaceutical Industries - Clinuvel Pharmaceuticals - Ache Laboratorios Farmaceuticos - SWITCH Biotech For more information visit http://www.researchandmarkets.com/research/sp334p/vitiligo
Market Maker Surveillance Report. RITT, GNI, GTI, GLYC, CLVLY, PULS, Losing Stocks With Lowest Price Friction For Friday, September 26th 2014
M2 - Mon Sep 29, 2:48AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4860 companies with "abnormal" market making, 3007 companies with positive Friction Factors and 1840 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), Great Northern Iron Ore Properties (NYSE:GNI), Graftech International Ltd (NYSE:GTI), GLYCOMED INC (NASDAQ:GLYC), Clinuvel Pharmaceuticals Ltd (OTC:CLVLY), Pulse Electronics Corp (NYSE
ULS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . GLYC: 7.10 (+0.09), GTI: 5.05 (+0.01), RITT: 1.38 (+0.05), GNI: 8.10 (+0.67)
